Beyond capacity, OSD projects require the right level of support. What's harder to find is continuity.
A product that moves from formulation development to validation to commercial launch with the same partner, the same quality logic, the same institutional knowledge.
And its absence costs more than people acknowledge upfront. Every handover between partners is a risk event: assumptions lost in translation, documentation gaps, reformulation under time pressure, regulatory questions reopened.
The real question when selecting an CDMO isn't "do they have the machines?" It's "can they go the distance with us?
That breadth matters not because we want to do everything, but because our customers shouldn't have to rebuild their project from scratch each time they move to the next phase. The industrial knowledge, the quality framework, the familiarity with the product — it stays in the room.
For pharmaceutical companies, choosing an Oral Solid Dose partner is not only about securing manufacturing capacity. It is about finding the right combination of development expertise, industrial reliability, quality oversight and packaging capabilities to move a product forward with confidence.
From early-stage development to commercial supply, OSD projects require continuity. Customers need a partner able to reduce complexity, support scale-up and ensure a smooth transition from one stage to the next. This is the logic behind FAREVA’s Oral Solid Dose offer.
What full-lifecycle support actually means
At FAREVA, our offer is built around this logic. We cover the full project arc, formulation and analytical development, process development, clinical batches, scale-up, validation, regulatory support and commercial manufacturing, across a platform that handles both conventional and high potent environments (OEB 1 through OEB 6).
This integrated approach helps create a more seamless path between development and industrialization. It also limits fragmentation across partners, which is often a major concern for pharmaceutical companies looking for consistency, speed and control.
Wide dosage form expertise across conventional and high potent environments
FAREVA’s OSD platform covers a broad range of dosage forms, including tablets, coated tablets, mini-tabs, hard capsules, granules and powders.
Its capabilities span both conventional and high potent environments, with:
- Conventional Oral Solid capabilities from OEB 1 to OEB 4
- High Potent Oral Solid capabilities from OEB 4 to OEB 6
For customers, this means access to a platform able to support a wide variety of product profiles, from standard oral solid forms to more demanding high potent compounds, with the appropriate level of containment and expertise.
Industrial footprint, packaging and quality expectations
FAREVA combines this technical breadth with a strong industrial footprint, including 7 conventional manufacturing sites and 1 dedicated high potent site.
The platform is also supported by packaging capabilities adapted to OSD products, such as:
- blisters
- bottles
- jars
- stick packs
- sachets
- serialization and aggregation
For pharmaceutical companies, these capabilities are not only about scale. They are also about execution. Customers want reassurance that their partner can combine industrial robustness, quality discipline and the ability to meet regulatory and market requirements across the value chain.
FAREVA’s approach is also supported by a strong quality and compliance framework, with accreditations and authorizations depending on the site. This contributes to the level of confidence customers expect when selecting a partner for regulated OSD projects.
Supporting OSD projects with confidence
Whether a project is still in development, entering validation or preparing for commercial launch, the expectation remains the same: working with a partner that can combine expertise, flexibility and reliability.
Selecting an OSD partner is a strategic decision. The companies that get it right are the ones that look beyond initial capacity figures and ask harder questions about development expertise, industrial reliability, quality discipline and project continuity.
That's the conversation we're ready to have. To discuss your next OSD project, contact pharma@fareva.com.
You can also meet FAREVA at upcoming industry events: DCAT Week, 23-26 March 2026, and CPHI Japan, 21-23 April 2026.